The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival

Selvakumar Elangovan, Rajneesh Pathania, Sabarish Ramachandran, Sudha Ananth, Ravi N. Padia, Ling Lan, Nagendra Singh, Pamela Moore Martin, Lesleyann Hawthorn, Puttur D Prasad, Vadivel Ganapathy, Muthusamy Thangaraju

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

GPR109A, a G-protein-coupled receptor, is activated by niacin and butyrate. Upon activation in colonocytes, GPR109A potentiates anti-inflammatory pathways, induces apoptosis, and protects against inflammation-induced colon cancer. In contrast, GPR109A activation in keratinocytes induces flushing by activation of Cox-2-dependent inflammatory signaling, and the receptor expression is upregulated in human epidermoid carcinoma. Thus, depending on the cellular context and tissue, GPR109A functions either as a tumor suppressor or a tumor promoter. However, the expression status and the functional implications of this receptor in the mammary epithelium are not known. Here, we show that GPR109A is expressed in normal mammary tissue and, irrespective of the hormone receptor status, its expression is silenced in human primary breast tumor tissues, breast cancer cell lines, and in tumor tissues of three different murine mammary tumor models. Functional expression of this receptor in human breast cancer cell lines decreases cyclic AMP production, induces apoptosis, and blocks colony formation and mammary tumor growth. Transcriptome analysis revealed that GPR109A activation inhibits genes, which are involved in cell survival and antiapoptotic signaling, in human breast cancer cells. In addition, deletion of Gpr109a in mice increased tumor incidence and triggered early onset of mammary tumorigenesis with increased lung metastasis in MMTV-Neu mouse model of spontaneous breast cancer. These findings suggest that GPR109A is a tumor suppressor in mammary gland and that pharmacologic induction of this gene in tumor tissues followed by its activation with agonists could be an effective therapeutic strategy to treat breast cancer.

Original languageEnglish (US)
Pages (from-to)1166-1178
Number of pages13
JournalCancer Research
Volume74
Issue number4
DOIs
StatePublished - Feb 15 2014

Fingerprint

Butyrates
Niacin
Cell Survival
Carcinogenesis
Breast
Breast Neoplasms
Neoplasms
Apoptosis
Gene Expression Profiling
Human Mammary Glands
G-Protein-Coupled Receptors
Tumor Cell Line
Keratinocytes
Carcinogens
Cyclic AMP
Colonic Neoplasms
Transcriptional Activation
Squamous Cell Carcinoma
Anti-Inflammatory Agents
Epithelium

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival. / Elangovan, Selvakumar; Pathania, Rajneesh; Ramachandran, Sabarish; Ananth, Sudha; Padia, Ravi N.; Lan, Ling; Singh, Nagendra; Martin, Pamela Moore; Hawthorn, Lesleyann; Prasad, Puttur D; Ganapathy, Vadivel; Thangaraju, Muthusamy.

In: Cancer Research, Vol. 74, No. 4, 15.02.2014, p. 1166-1178.

Research output: Contribution to journalArticle

Elangovan S, Pathania R, Ramachandran S, Ananth S, Padia RN, Lan L et al. The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival. Cancer Research. 2014 Feb 15;74(4):1166-1178. https://doi.org/10.1158/0008-5472.CAN-13-1451
Elangovan, Selvakumar ; Pathania, Rajneesh ; Ramachandran, Sabarish ; Ananth, Sudha ; Padia, Ravi N. ; Lan, Ling ; Singh, Nagendra ; Martin, Pamela Moore ; Hawthorn, Lesleyann ; Prasad, Puttur D ; Ganapathy, Vadivel ; Thangaraju, Muthusamy. / The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival. In: Cancer Research. 2014 ; Vol. 74, No. 4. pp. 1166-1178.
@article{1c7f5e3de230464f9e2a84b8fea962a5,
title = "The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival",
abstract = "GPR109A, a G-protein-coupled receptor, is activated by niacin and butyrate. Upon activation in colonocytes, GPR109A potentiates anti-inflammatory pathways, induces apoptosis, and protects against inflammation-induced colon cancer. In contrast, GPR109A activation in keratinocytes induces flushing by activation of Cox-2-dependent inflammatory signaling, and the receptor expression is upregulated in human epidermoid carcinoma. Thus, depending on the cellular context and tissue, GPR109A functions either as a tumor suppressor or a tumor promoter. However, the expression status and the functional implications of this receptor in the mammary epithelium are not known. Here, we show that GPR109A is expressed in normal mammary tissue and, irrespective of the hormone receptor status, its expression is silenced in human primary breast tumor tissues, breast cancer cell lines, and in tumor tissues of three different murine mammary tumor models. Functional expression of this receptor in human breast cancer cell lines decreases cyclic AMP production, induces apoptosis, and blocks colony formation and mammary tumor growth. Transcriptome analysis revealed that GPR109A activation inhibits genes, which are involved in cell survival and antiapoptotic signaling, in human breast cancer cells. In addition, deletion of Gpr109a in mice increased tumor incidence and triggered early onset of mammary tumorigenesis with increased lung metastasis in MMTV-Neu mouse model of spontaneous breast cancer. These findings suggest that GPR109A is a tumor suppressor in mammary gland and that pharmacologic induction of this gene in tumor tissues followed by its activation with agonists could be an effective therapeutic strategy to treat breast cancer.",
author = "Selvakumar Elangovan and Rajneesh Pathania and Sabarish Ramachandran and Sudha Ananth and Padia, {Ravi N.} and Ling Lan and Nagendra Singh and Martin, {Pamela Moore} and Lesleyann Hawthorn and Prasad, {Puttur D} and Vadivel Ganapathy and Muthusamy Thangaraju",
year = "2014",
month = "2",
day = "15",
doi = "10.1158/0008-5472.CAN-13-1451",
language = "English (US)",
volume = "74",
pages = "1166--1178",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival

AU - Elangovan, Selvakumar

AU - Pathania, Rajneesh

AU - Ramachandran, Sabarish

AU - Ananth, Sudha

AU - Padia, Ravi N.

AU - Lan, Ling

AU - Singh, Nagendra

AU - Martin, Pamela Moore

AU - Hawthorn, Lesleyann

AU - Prasad, Puttur D

AU - Ganapathy, Vadivel

AU - Thangaraju, Muthusamy

PY - 2014/2/15

Y1 - 2014/2/15

N2 - GPR109A, a G-protein-coupled receptor, is activated by niacin and butyrate. Upon activation in colonocytes, GPR109A potentiates anti-inflammatory pathways, induces apoptosis, and protects against inflammation-induced colon cancer. In contrast, GPR109A activation in keratinocytes induces flushing by activation of Cox-2-dependent inflammatory signaling, and the receptor expression is upregulated in human epidermoid carcinoma. Thus, depending on the cellular context and tissue, GPR109A functions either as a tumor suppressor or a tumor promoter. However, the expression status and the functional implications of this receptor in the mammary epithelium are not known. Here, we show that GPR109A is expressed in normal mammary tissue and, irrespective of the hormone receptor status, its expression is silenced in human primary breast tumor tissues, breast cancer cell lines, and in tumor tissues of three different murine mammary tumor models. Functional expression of this receptor in human breast cancer cell lines decreases cyclic AMP production, induces apoptosis, and blocks colony formation and mammary tumor growth. Transcriptome analysis revealed that GPR109A activation inhibits genes, which are involved in cell survival and antiapoptotic signaling, in human breast cancer cells. In addition, deletion of Gpr109a in mice increased tumor incidence and triggered early onset of mammary tumorigenesis with increased lung metastasis in MMTV-Neu mouse model of spontaneous breast cancer. These findings suggest that GPR109A is a tumor suppressor in mammary gland and that pharmacologic induction of this gene in tumor tissues followed by its activation with agonists could be an effective therapeutic strategy to treat breast cancer.

AB - GPR109A, a G-protein-coupled receptor, is activated by niacin and butyrate. Upon activation in colonocytes, GPR109A potentiates anti-inflammatory pathways, induces apoptosis, and protects against inflammation-induced colon cancer. In contrast, GPR109A activation in keratinocytes induces flushing by activation of Cox-2-dependent inflammatory signaling, and the receptor expression is upregulated in human epidermoid carcinoma. Thus, depending on the cellular context and tissue, GPR109A functions either as a tumor suppressor or a tumor promoter. However, the expression status and the functional implications of this receptor in the mammary epithelium are not known. Here, we show that GPR109A is expressed in normal mammary tissue and, irrespective of the hormone receptor status, its expression is silenced in human primary breast tumor tissues, breast cancer cell lines, and in tumor tissues of three different murine mammary tumor models. Functional expression of this receptor in human breast cancer cell lines decreases cyclic AMP production, induces apoptosis, and blocks colony formation and mammary tumor growth. Transcriptome analysis revealed that GPR109A activation inhibits genes, which are involved in cell survival and antiapoptotic signaling, in human breast cancer cells. In addition, deletion of Gpr109a in mice increased tumor incidence and triggered early onset of mammary tumorigenesis with increased lung metastasis in MMTV-Neu mouse model of spontaneous breast cancer. These findings suggest that GPR109A is a tumor suppressor in mammary gland and that pharmacologic induction of this gene in tumor tissues followed by its activation with agonists could be an effective therapeutic strategy to treat breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84894261181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894261181&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-1451

DO - 10.1158/0008-5472.CAN-13-1451

M3 - Article

C2 - 24371223

AN - SCOPUS:84894261181

VL - 74

SP - 1166

EP - 1178

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 4

ER -